Literature DB >> 9630382

Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects.

P Marckmann1, S Toubro, A Astrup.   

Abstract

OBJECTIVE: To study whether major weight loss causes sustained improvement in blood lipids and haemostatic profile in obese subjects, and to compare the influence of two different slimming and maintenance regimens.
DESIGN: Two-stranded randomized intervention study.
SETTING: University Department.
SUBJECTS: Thirty-six out of 43 obese patients recruited from out-patient waiting list completed the study.
INTERVENTIONS: Weight loss was achieved by very low energy formula diet (2 MJ/d for 8 weeks, n=18), or low-energy conventional diet (5 MJ/d for 17 weeks, n=18), both combined with anorectic compound. Participants were re-randomized to consume low fat diet ad libitum (n=16), or energy-restricted diet (n=20) for weight maintenance during 24 weeks. MAIN OUTCOME MEASURES: Plasma lipids, fibrinogen, factor VII coagulant activity (FVIIc), and plasminogen activator inhibitor type 1 (PAI-1) antigen.
RESULTS: Weight loss averaged 13.6 kg (95% CI: 12.3-14.9 kg). After 24 weeks' weight maintenance, plasma total cholesterol was 9% lower, high density lipoprotein cholesterol 5% higher, triglycerides 30% lower, FVIIc 12% lower, fibrinogen 6% lower, and PAI-1 antigen 34% lower than at baseline (all changes highly significant). There were no significant differences between slimming or maintenance regimens.
CONCLUSIONS: Major weight loss is associated with sustained and marked improvements in blood lipids and hemostatic profile, irrespective of the tested slimming and maintenance regimens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9630382     DOI: 10.1038/sj.ejcn.1600558

Source DB:  PubMed          Journal:  Eur J Clin Nutr        ISSN: 0954-3007            Impact factor:   4.016


  11 in total

1.  Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study.

Authors:  H Hämäläinen; T Rönnemaa; A Virtanen; J Lindström; J G Eriksson; T T Valle; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Rastas; S Aunola; M Uusitupa; J Tuomilehto
Journal:  Diabetologia       Date:  2005-10-05       Impact factor: 10.122

2.  Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance.

Authors:  Steven Haffner; Marinella Temprosa; Jill Crandall; Sarah Fowler; Ronald Goldberg; Edward Horton; Santica Marcovina; Kieren Mather; Trevor Orchard; Robert Ratner; Elizabeth Barrett-Connor
Journal:  Diabetes       Date:  2005-05       Impact factor: 9.461

3.  Parameters of inflammation in morbid obesity: lack of effect of moderate weight loss.

Authors:  Eva Solá; Ana Jover; Antonio López-Ruiz; María Jarabo; Amparo Vayá; Carlos Morillas; Marcelino Gómez-Balaguer; Antonio Hernández-Mijares
Journal:  Obes Surg       Date:  2008-12-03       Impact factor: 4.129

4.  Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure - A Pilot Study.

Authors:  Allison M Pritchett; Anita Deswal; David Aguilar; John P Foreyt; Wenyaw Chan; Douglas L Mann; Christie Ballantyne; Biykem Bozkurt
Journal:  J Obes Weight Loss Ther       Date:  2012-03-15

5.  Comparison of early and late changes in immunoglobulins and acute phase reactants after laparoscopic adjustable gastric banding in patients with morbid obesity.

Authors:  Ibrahim Sakçak; Mehmet Fatih Avşar; Enver Okan Hamamci; Settar Bostanoğlu; Muhittin Sonişik; Akin Bostanoğlu; Nihal Zekiye Erdem; Erdal Coşgun
Journal:  Obes Surg       Date:  2010-01-12       Impact factor: 4.129

Review 6.  The hematologic consequences of obesity.

Authors:  Johanna C Purdy; Joseph J Shatzel
Journal:  Eur J Haematol       Date:  2020-12-13       Impact factor: 2.997

7.  Effect of weight loss on adipokine levels in obese patients.

Authors:  Catherine Rolland; Michelle Hession; Iain Broom
Journal:  Diabetes Metab Syndr Obes       Date:  2011-08-03       Impact factor: 3.168

8.  Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study.

Authors:  Jenny Hernestål-Boman; Margareta Norberg; Jan-Hakan Jansson; Mats Eliasson; Jan W Eriksson; Bernt Lindahl; Lars Johansson
Journal:  Cardiovasc Diabetol       Date:  2012-12-18       Impact factor: 9.951

9.  Reduced fibrinogen, fibrinolytic biomarkers, and physical parameters after a weight-loss program in obese subjects.

Authors:  Che Badariah Abdul Aziz; Norsuhana Omar; Wan Zaidah Abdullah; Rohana Abdul Jalil; Wan Suriati Wan Nik; Rahimah Zakaria
Journal:  N Am J Med Sci       Date:  2014-08

Review 10.  Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies.

Authors:  James Yarmolinsky; Natália Bordin Barbieri; Tobias Weinmann; Patricia K Ziegelmann; Bruce B Duncan; Maria Inês Schmidt
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.